{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PARP+Inhibitor&page=2", "query": { "condition": "PARP Inhibitor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PARP+Inhibitor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T15:33:05.072Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer", "Additional Indications Below for Module 4 and 5", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Bladder Cancer", "Gastric Cancer", "Biliary Cancer", "Cervical Cancer", "Endometrial Cancer", "Small Cell Lung Cancer Only in Module 5" ], "interventions": [ { "name": "AZD5305", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "T- Dxd", "type": "DRUG" }, { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Camizestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 702, "start_date": "2020-11-12", "completion_date": "2027-05-28", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-07-22T15:33:05.072Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644068" }, { "nct_id": "NCT03830918", "title": "Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Extensive Stage Lung Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Niraparib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2019-03-06", "completion_date": "2027-01-03", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-07-22T15:33:05.072Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03830918" }, { "nct_id": "NCT02163694", "title": "A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Veliparib Placebo", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 513, "start_date": "2014-04-08", "completion_date": "2024-01-25", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-07-22T15:33:05.072Z", "location_count": 56, "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02163694" }, { "nct_id": "NCT00678132", "title": "AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "AZD 2281", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2008-04-24", "completion_date": "2010-11-23", "has_results": false, "last_update_posted_date": "2018-07-05", "last_synced_at": "2026-07-22T15:33:05.072Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00678132" }, { "nct_id": "NCT02975934", "title": "A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Rucaparib", "type": "DRUG" }, { "name": "Abiraterone acetate or Enzalutamide or Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "pharmaand GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 405, "start_date": "2017-06-13", "completion_date": "2024-08-08", "has_results": true, "last_update_posted_date": "2025-07-25", "last_synced_at": "2026-07-22T15:33:05.072Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Laguna Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02975934" }, { "nct_id": "NCT06161493", "title": "ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Recurrent Solid Tumors" ], "interventions": [ { "name": "ZEN003694", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Haider Mahdi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-01-23", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-07-22T15:33:05.072Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06161493" }, { "nct_id": "NCT04729387", "title": "Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 358, "start_date": "2021-07-22", "completion_date": "2026-01-19", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-07-22T15:33:05.072Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Fort Myers, Florida • West Palm Beach, Florida + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729387" }, { "nct_id": "NCT02898207", "title": "Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic High Grade Fallopian Tube Serous Adenocarcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Primary Peritoneal Serous Adenocarcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Breast Carcinoma", "Recurrent High Grade Fallopian Tube Serous Adenocarcinoma", "Recurrent High Grade Ovarian Serous Adenocarcinoma", "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma", "Recurrent Triple-Negative Breast Carcinoma", "Refractory Fallopian Tube Serous Adenocarcinoma", "Refractory Ovarian Serous Adenocarcinoma", "Refractory Primary Peritoneal Serous Adenocarcinoma", "Refractory Triple-Negative Breast Carcinoma", "Unresectable High Grade Fallopian Tube Serous Adenocarcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Primary Peritoneal Serous Adenocarcinoma" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Onalespib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2017-05-19", "completion_date": "2022-01-14", "has_results": true, "last_update_posted_date": "2023-04-26", "last_synced_at": "2026-07-22T15:33:05.072Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02898207" }, { "nct_id": "NCT04917744", "title": "Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Medical Chart Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 5, "start_date": "2021-04-01", "completion_date": "2024-02-17", "has_results": false, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-07-22T15:33:05.072Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04917744" }, { "nct_id": "NCT04209686", "title": "Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Gastric Adenocarcinoma" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2020-07-31", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-07-22T15:33:05.072Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04209686" } ] }